» Articles » PMID: 2856541

Failures of Intravenous Rh Immune Globulin Prophylaxis: an Analysis of the Reasons for Such Failures

Overview
Specialty Hematology
Date 1987 Aug 1
PMID 2856541
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Universal administration of an ion exchange column prepared Rh immune globulin (RhIG-IV) antepartum at 28 weeks' gestation and postpartum to 9,295 Rh negative women delivering Rh positive babies has reduced the prevalence of Rh immunization from the expected 601 to 25 (a protection rate of 95.9%). Rh immunization, despite universal Rh prophylaxis, developed in 25 women; eight before antenatal prophylaxis was administered, 17 after antenatal prophylaxis was administered. Residual Rh immunization is caused by small fetal transplacental hemorrhages (TPH) (greater than or equal to 0.01 mL of fetal blood) before antenatal prophylaxis (15%) and by significant fetal TPH (greater than or equal to 0.05 mL of fetal blood) between 30 and 38 weeks' gestation (18%); TPH was too great, in some instances, for residual passive Rh antibody to give protection. Although a reduction of 62% (five of eight) of early Rh immunization and 82% (14 of 17) of later Rh immunization might be achieved by addition of 16 weeks' to 20 weeks' gestation and 34 weeks' gestation Rh prophylaxis; and a reduction of 84% overall (21 of 25) might be achieved by universal fetal TPH screening every 2 weeks from 10 weeks' gestation until delivery, with administration of RhIG when a small early fetal TPH or a significant later fetal TPH is detected, all of these programs are costly in terms of prevention of perinatal mortality and in terms of cost per quality adjusted life year gained. We believe that the costs outweigh the benefit that would be achieved. Therefore, a residual Rh immunization prevalence of 0.24% to 0.31% during or after each Rh positive pregnancy in patients at risk is to be expected despite universal 28 weeks' gestation antenatal and postnatal Rh prophylaxis.

Citing Articles

Another piece of the hemolytic disease of the fetus and newborn puzzle after RhD-positive transfusion in trauma resuscitation: the proportion of pregnant women who produce high titer anti-D.

Yazer M, Emery S, Triulzi D, Spinella P, Leeper C Trauma Surg Acute Care Open. 2024; 9(Suppl 1):e001252.

PMID: 38196928 PMC: 10773421. DOI: 10.1136/tsaco-2023-001252.


Application of flow cytometry in transfusion medicine: The Sanjay Gandhi Post Graduate Institute of Medical Sciences, India experience.

Chaudhary R, Das S Asian J Transfus Sci. 2023; 16(2):159-166.

PMID: 36687536 PMC: 9855202. DOI: 10.4103/ajts.ajts_61_22.


Complement Plays a Critical Role in Inflammation-Induced Immunoprophylaxis Failure in Mice.

Escamilla-Rivera V, Santhanakrishnan M, Liu J, Gibb D, Forsmo J, Foxman E Front Immunol. 2021; 12:704072.

PMID: 34249009 PMC: 8270673. DOI: 10.3389/fimmu.2021.704072.


Clinical value of different anti-D immunoglobulin strategies for preventing Rh hemolytic disease of the fetus and newborn: A network meta-analysis.

Xie X, Fu Q, Bao Z, Zhang Y, Zhou D PLoS One. 2020; 15(3):e0230073.

PMID: 32163467 PMC: 7067404. DOI: 10.1371/journal.pone.0230073.


Recommendations for the prevention and treatment of haemolytic disease of the foetus and newborn.

Bennardello F, Coluzzi S, Curciarello G, Todros T, Villa S Blood Transfus. 2015; 13(1):109-34.

PMID: 25633877 PMC: 4317097. DOI: 10.2450/2014.0119-14.